Technical Analysis for CYP - Cynata Therapeutics Ltd  

Grade Last Price % Change Price Change
C 0.225 -8.16% -0.020
CYP closed down 8.16 percent on Monday, November 18, 2024, on 1.42 times normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline. The stock fell below its 200 day moving average, damaging its long-term outlook by crossing under that critical trendline.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
Bearish Engulfing Bearish 0.00%
Fell Below 20 DMA Bearish 0.00%
Fell Below 200 DMA Bearish 0.00%
Fell Below 50 DMA Bearish 0.00%
Expansion Pivot Sell Setup Bearish Swing Setup 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
Golden Cross Bullish -8.16%
MACD Bullish Centerline Cross Bullish -8.16%
Expansion Pivot Buy Setup Bullish Swing Setup -8.16%
Bollinger Band Squeeze Range Contraction -8.16%

   Recent Intraday Alerts

Alert Time
20 DMA Support about 6 hours ago
200 DMA Support about 7 hours ago
50 DMA Support about 7 hours ago
Down 1 ATR about 7 hours ago
Fell Below Previous Day's Low about 7 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Cynata Therapeutics Ltd   Description

Cynata Therapeutics Limited is a stem cell and regenerative medicine company. The Company is engaged in the development and commercialization of a mesenchymal stem cell (MSC) technology for human therapeutic use, Cymerus. Its Cymerus technology facilitates manufacture of MSCs from a single donor and a single donation. The Company's Cymerus platform stem cell technology is based upon stem cells known as mesenchymoangioblasts (MCAs). The Company's technology utilizes induced pluripotent stem cells (iPSCs) originating from an adult donor as the starting material for generating MCAs and in turn for manufacturing the MSC therapeutic product. The Cymerus platform provides a source of MSCs that is independent of donor limitations and provides an off-the-shelf stem cell platform for therapeutic product use. The Company's MSCs produced using Cymerus technology, can be used to treat unrelated patients, without any need to match the recipient to the donor.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Manufacturing Medicine Biotechnology Life Sciences Biology Therapeutic Product Regenerative Medicine Regenerative Stem Cell Stem Cells Cell Biology Induced Stem Cells Mesenchymal Stem Cell The Star

Is CYP a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 0.345
52 Week Low 0.105
Average Volume 100,604
200-Day Moving Average 0.227
50-Day Moving Average 0.227
20-Day Moving Average 0.231
10-Day Moving Average 0.229
Average True Range 0.011
RSI (14) 46.81
ADX 14.47
+DI 24.242
-DI 18.624
Chandelier Exit (Long, 3 ATRs) 0.221
Chandelier Exit (Short, 3 ATRs) 0.254
Upper Bollinger Bands 0.246
Lower Bollinger Band 0.216
Percent B (%b) 0.29
BandWidth 13.057
MACD Line 0.000
MACD Signal Line 0.000
MACD Histogram 0.0003
Fundamentals Value
Market Cap 26.35 Million
Num Shares 117 Million
EPS -0.09
Price-to-Earnings (P/E) Ratio -2.65
Price-to-Sales 0.00
Price-to-Book 5.58
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.255
Resistance 3 (R3) 0.258 0.252 0.250
Resistance 2 (R2) 0.252 0.244 0.250 0.248
Resistance 1 (R1) 0.238 0.239 0.235 0.235 0.247
Pivot Point 0.232 0.232 0.230 0.230 0.232
Support 1 (S1) 0.218 0.224 0.215 0.215 0.203
Support 2 (S2) 0.212 0.219 0.210 0.202
Support 3 (S3) 0.198 0.212 0.200
Support 4 (S4) 0.195